Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123863 | 0.83 | BLM (0.46) | MAPTDRD3BLMFDPSNPSR1 | |
| SCHEMBL29510648 | 0.77 | GABBR2 (0.36) | CHRM2CHRM4CHRM1CHRM3FDPS | |
| SCHEMBL15434518 | 0.76 | HTR1A (0.37) | MAPTDRD3BLM | |
| SCHEMBL29344807 | 0.74 | MAPT (0.33) | MAPT | |
| SCHEMBL6738457 | 0.74 | MAPT (0.48) | MAPT | |
| SCHEMBL15268543 | 0.73 | MEN1 (0.30) | — | |
| SCHEMBL121180 | 0.72 | MEN1 (0.39) | — | |
| SCHEMBL7869696 | 0.72 | MEN1 (0.39) | — | |
| SCHEMBL5054651 | 0.72 | — | — | |
| Alcohol SCHEMBL2319134 | 0.71 | MEN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087980-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | claimed |
| EP-3678659-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | Eagle Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| WO-2020112766-A1 | COMPOSITIONS AND METHODS FOR TREATING NERVE AGENT EXPOSURE | HOFFMAN STEVEN (US) | 2020-06-04 | — | — | WO | claimed |
| US-20200163952-A1 | COMPOSITIONS AND METHODS FOR TREATING NERVE AGENT EXPOSURE | HOFFMAN STEVEN (US) | 2020-05-28 | — | — | US | claimed |
| CN-111093652-A | Methods of treating nerve agent exposure using dantrolene | 伊格尔制药公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019050923-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | claimed |
| US-11547667-B2 | Vaccine nanotechnology | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-01-10 | — | — | US | disclosed |
| US-11352347-B2 | Dantrolene prodrugs and methods of their use | Eagle Research Labs Limited (MT) | 2022-06-07 | — | — | US | disclosed |
| US-20220087980-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20210236467-A1 | DANTROLENE FORMULATIONS AND METHODS OF THEIR USE | EAGLE PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3796889-A1 | DANTROLENE FORMULATIONS AND METHODS OF THEIR USE | Eagle Pharmaceuticals, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-112135605-A | Dantrolene formulations and methods of use thereof | 伊格尔制药公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20100183727-A1 | Immunonanotherapeutics that Provide IgG Humoral Response Without T-Cell Antigen | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-07-22 | — | — | US | disclosed |
| US-20100129439-A1 | Adjuvant Incorporation in Immunonanotherapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-05-27 | — | — | US | disclosed |
| US-20100129392-A1 | Targeting of Antigen Presenting Cells with Immunonanotherapeutics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100092425-A1 | Nicotine Immunonanotherapeutics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| WO-2009051837-A2 | VACCINE NANOTECHNOLOGY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-04-23 | — | — | WO | disclosed |
| CN-1735417-A | Method of treating patients exposed to toxic chemicals | BIONUMERIK PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | CN | disclosed |
| US-4112082-A | Pharmaceutical composition for treating glaucoma and compound 1,3,2-dioxaphospheringnes | The State of Israel, Prime Minister's Office, The Israel Institute for Biological Research (IL) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129392-A1 | Targeting of Antigen Presenting Cells with Immunonanotherapeutics | CD74, CD4, ICOS | MAPT 1798/4885DRD3 2517/4885BLM 3961/4885 |
| US-20220087980-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | PMP22, CNTN1, SMN1; SMN2 | MAPT 1073/4885DRD3 1212/4885BLM 1246/4885 |
| US-20100129439-A1 | Adjuvant Incorporation in Immunonanotherapeutics | ICOS, CD47, CD4 | MAPT 3576/4885DRD3 2242/4885BLM 1175/4885 |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | PMP22, CNTN1, SMN1; SMN2 | MAPT 1073/4885DRD3 1212/4885BLM 1246/4885 |
| US-20210236467-A1 | DANTROLENE FORMULATIONS AND METHODS OF THEIR USE | SMN1; SMN2, LIPA, LCLAT1 | MAPT 205/4885DRD3 770/4885BLM 1344/4885 |
| US-20100183727-A1 | Immunonanotherapeutics that Provide IgG Humoral Response Without T-Cell Antigen | FCGR3B, FCGR1A, FCGR2A | MAPT 1683/4885DRD3 2491/4885BLM 3578/4885 |
| US-11352347-B2 | Dantrolene prodrugs and methods of their use | BID, TPMT, CES2 | MAPT 1491/4885DRD3 2518/4885BLM 1708/4885 |
| US-20100092425-A1 | Nicotine Immunonanotherapeutics | CD4, CD47, FCGR3B | MAPT 1216/4885DRD3 160/4885BLM 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.